Narcolepsy drugs linked to birth defects in offspring finds JAMA study
Israel: The use of narcolepsy drugs armodafinil (Nuvigil) and modafinil (Provigil) during pregnancy may increase the risk for major congenital malformations in offspring, according to a report from the US Provigil/Nuvigil Pregnancy Registry -- a post-marketing requirement with annual data being reported to the US Food and Drug Administration. It was established to evaluated fetal and pregnancy outcomes in women who received these drugs during pregnancy.
The results are published in the journal JAMA Internal Medicine.
Sigal Kaplan, Teva Pharmaceutical Industries Ltd, Netanya, Israel, and colleagues studied about 150 women who used either drug in the 6 weeks before conception or during pregnancy. From February 2010 to February 2019, 148 individuals enrolled in the registry: 122 pregnancies were classified as prospective and 26 as retrospective. In total, 81 women received modafinil during pregnancy, 66 received armodafinil, and one received both drugs. Narcolepsy was the main indication (70%).
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.